CELL & GENE MEETING ON THE MESA 2022 NEWS
Cell & Gene Meeting on the Mesa 2022 Recap
November 9, 2022 -- The Science and Medicine Group team was onsite at this year's Cell & Gene Meeting on the Mesa getting the who, what, and when on the product announcements, science sessions, and deals taking place this year. Find out what we learned in our recap.
November 9, 2022 -- The Science and Medicine Group team was onsite at this year's Cell & Gene Meeting on the Mesa getting the who, what, and when on the product announcements, science sessions, and deals taking place this year. Find out what we learned in our recap.
Academic CDMOs, like commercial ones, play critical role in CGT sector
October 27, 2022 -- The cell and gene therapy (CGT) industry is growing and academic contract development and manufacturing organizations (CDMOs) -- like their larger commercial counterparts -- are playing a critical role in the ecosystem, according to Stuart Curbishley, PhD, head of business and process development at the University of Birmingham’s Advanced Therapies Facility.
October 27, 2022 -- The cell and gene therapy (CGT) industry is growing and academic contract development and manufacturing organizations (CDMOs) -- like their larger commercial counterparts -- are playing a critical role in the ecosystem, according to Stuart Curbishley, PhD, head of business and process development at the University of Birmingham’s Advanced Therapies Facility.
Induced pluripotent stem cell technology offers potential treatment for hair loss
October 25, 2022 -- Science Advisory Board spoke with Stemson Therapeutics co-founder and CEO Geoff Hamilton earlier this month at the 2022 Cell & Gene Meeting on the Mesa about the preclinical stage cell therapy company's focus on curing hair loss by leveraging the regenerative power of induced pluripotent stem cells.
October 25, 2022 -- Science Advisory Board spoke with Stemson Therapeutics co-founder and CEO Geoff Hamilton earlier this month at the 2022 Cell & Gene Meeting on the Mesa about the preclinical stage cell therapy company's focus on curing hair loss by leveraging the regenerative power of induced pluripotent stem cells.
Cell therapy startup NKILT Therapeutics takes novel approach to targeting leukemia
October 24, 2022 -- Biotech startup NKILT Therapeutics is developing a novel approach of engineering natural killer cells to directly target leukemias and solid tumors. Science Advisory Board spoke with Raphaël Ognar, co-founder and CEO of the company earlier this month at the 2022 Cell & Gene Meeting on the Mesa in Carlsbad, CA.
October 24, 2022 -- Biotech startup NKILT Therapeutics is developing a novel approach of engineering natural killer cells to directly target leukemias and solid tumors. Science Advisory Board spoke with Raphaël Ognar, co-founder and CEO of the company earlier this month at the 2022 Cell & Gene Meeting on the Mesa in Carlsbad, CA.
Antion Biosciences takes allogeneic approach to therapies with microRNA technology
October 21, 2022 -- Science Advisory Board spoke with Dr. Sven Kili, CEO of Antion Biosciences, at last week’s 2022 Cell & Gene Meeting on the Mesa, where he laid out his vision for where the company is heading and what the industry needs to do to cure diseases with significant unmet medical needs.
October 21, 2022 -- Science Advisory Board spoke with Dr. Sven Kili, CEO of Antion Biosciences, at last week’s 2022 Cell & Gene Meeting on the Mesa, where he laid out his vision for where the company is heading and what the industry needs to do to cure diseases with significant unmet medical needs.
CDMO Lonza continues drive to support cell and gene therapy commercial customers
October 20, 2022 -- In an interview with Science Advisory Board, Alberto Santagostino, senior vice president and head of cell and gene technologies at Swiss contract development and manufacturing organization (CDMO) Lonza, discussed bluebird bio's two recent U.S. Food and Drug Administration-approved gene therapies.
October 20, 2022 -- In an interview with Science Advisory Board, Alberto Santagostino, senior vice president and head of cell and gene technologies at Swiss contract development and manufacturing organization (CDMO) Lonza, discussed bluebird bio's two recent U.S. Food and Drug Administration-approved gene therapies.
GenNext wins $250K grand prize at 2022 BioTools Innovator capstone event
October 19, 2022 -- GenNext Technologies, a growth-stage company that enables analysis of protein higher order structure to improve and accelerate drug discovery development, won a $250,000 grand prize at the 2022 BioTools Innovator capstone event on October 13 in Carlsbad, CA.
October 19, 2022 -- GenNext Technologies, a growth-stage company that enables analysis of protein higher order structure to improve and accelerate drug discovery development, won a $250,000 grand prize at the 2022 BioTools Innovator capstone event on October 13 in Carlsbad, CA.
Cell and gene therapy sector is in midst of an ‘industrial revolution’: Miguel Forte
October 18, 2022 -- Science Advisory Board spoke with Dr. Miguel Forte, CEO of Bone Therapeutics and president-elect of the International Society for Cell & Gene Therapy, at last week’s 2022 Cell & Gene Meeting on the Mesa about the state of the cell and gene therapy sector.
October 18, 2022 -- Science Advisory Board spoke with Dr. Miguel Forte, CEO of Bone Therapeutics and president-elect of the International Society for Cell & Gene Therapy, at last week’s 2022 Cell & Gene Meeting on the Mesa about the state of the cell and gene therapy sector.
Platform enables precise, efficient delivery of genetic medicines in vivo
October 17, 2022 -- Biotech company Homology Medicines is leveraging 15 human hematopoietic stem cell-derived adeno-associated virus vectors to precisely and efficiently deliver genetic medicines in vivo via gene therapy or nuclease-free gene editing modality. CEO Albert Seymour spoke with Science Advisory Board about their platform.
October 17, 2022 -- Biotech company Homology Medicines is leveraging 15 human hematopoietic stem cell-derived adeno-associated virus vectors to precisely and efficiently deliver genetic medicines in vivo via gene therapy or nuclease-free gene editing modality. CEO Albert Seymour spoke with Science Advisory Board about their platform.
Manufacturing remains big challenge for cell and gene therapy industry
October 17, 2022 -- Science Advisory Board spoke with Eric Blair, chief commercial officer for Andelyn Biosciences, at last week’s 2022 Cell & Gene Meeting on the Mesa about the challenges of manufacturing to meet growing demand in the cell and gene therapy industry.
October 17, 2022 -- Science Advisory Board spoke with Eric Blair, chief commercial officer for Andelyn Biosciences, at last week’s 2022 Cell & Gene Meeting on the Mesa about the challenges of manufacturing to meet growing demand in the cell and gene therapy industry.